Volume 15, Number 9—September 2009
Dispatch
Population-based Surveillance for Hepatitis C Virus, United States, 2006–2007
, Jeremy Miller, Candace Vonderwahl, Suzanne Speers, Karen Alelis, Kristin Sweet, Elena Rocchio, Tasha Poissant, Tara M. Vogt, and Kathleen Gallagher
Table
Newly reported cases of past or present HCV infection in 6 US locations, July 1, 2006–June 30, 2007*†
| Characteristic | Colorado | Connecticut | Minnesota | New York‡ | Oregon | Pinellas County, Florida | Total |
|---|---|---|---|---|---|---|---|
| Estimated population, 2007 | 4,862,000 | 3,502,000 | 5,198,000 | 11,068,000 | 3,747,000 | 924,000 | 29,301,000 |
| Year registry initiated |
1993 |
1994 |
1998 |
2003 |
2005 |
1999 |
|
| Sex, no. (%) | |||||||
| F | 1,088 (36.5) | 1,360 (35.9) | 494 (37.6) | 2,882 (30.4) | 711 (34.9) | 302 (45.4) | 6,837 (33.8) |
| M | 1,879 (63.0) | 2,429 (64.1) | 804 (61.2) | 6,595 (69.5) | 1,285 (63.0) | 359 (54.0) | 13,351 (66.0) |
| Unknown |
16 (0.5) |
3 (0.1) |
15 (1.1) |
15 (0.2) |
44 (2.2) |
4 (0.6) |
53 (0.3) |
| Age group, y, no. (%) | |||||||
| 0–14 | 16 (0.5) | 9 (0.2) | 10 (0.8) | 14 (0.2) | 9 (0.4) | 5 (0.8) | 63 (0.3) |
| 15–24 | 126 (4.2) | 127 (3.4) | 37 (2.8) | 318 (3.4) | 55 (2.7) | 25 (3.8) | 688 (3.4) |
| 25–39 | 638 (21.4) | 741 (19.5) | 200 (15.2) | 1,527 (16.1) | 386 (18.9) | 69 (10.4) | 3,561 (17.6) |
| 40–54 | 1,645 (55.2) | 2,158 (56.9) | 798 (60.8) | 5,153 (54.3) | 1,149 (56.3) | 411 (61.8) | 11,314 (56.0) |
| >55 | 546 (18.3) | 755 (19.9) | 267 (20.3) | 2,438 (25.7) | 422 (20.7) | 155 (23.3) | 4,583 (22.7) |
| Unknown |
12 (0.4) |
2 (0.0) |
1 (0.1) |
42 (0.4) |
19 (0.9) |
0 |
76 (0.4) |
| Case criteria, no. (%)§ | |||||||
| Anti-HCV and supplemental test | 593 (19.9) | 1,520 (40.1) | 520 (39.6) | 3,763 (39.6) | 203 (10.0) | 0 | 6,599 (32.5) |
| RIBA | 527 (17.7) | 466 (12.3) | 384 (29.3) | 1,404 (14.8) | 185 (9.1) | 15 (2.3) | 2,981 (14.7) |
| HCV RNA | 1,245 (41.7) | 1,984 (52.3) | 928 (70.7) | 5,831 (61.4) | 818 (40.1) | 28 (4.2) | 10,834 (53.4) |
| Genotype | 586 (19.6) | 21 (0.6) | 304 (23.2) | 1,473 (15.5) | 207 (10.2) | 142 (21.4) | 2,733 (13.5) |
| Anti-HCV and s:co ratio |
1,859 (62.3) |
1,352 (35.7) |
253 (19.3) |
4,709 (49.6) |
905 (44.4) |
521 (78.4) |
9,599 (47.3) |
| Source of report, no. (%) | |||||||
| Laboratory | 2,561 (85.9) | 3,792 (100.0) | 878 (66.9) | 8,252 (86.9) | 1,923 (94.3) | 592 (89.0) | 17,998 (88.7) |
| Others, combined¶ |
422 (14.2) |
0 |
435 (33.1) |
1,240 (13.1) |
117 (5.7) |
73 (11.0) |
2,287 (11.3) |
| Total reports | 2,983 | 3,792 | 1,313 | 9,492 | 2,040 | 665 | 20,285 |
| Report rate/100,000 population | 61.4 | 108.3 | 25.3 | 85.8 | 54.4 | 71.9 | 69.2 |
*HCV, hepatitis C virus; RIBA, recombinant immunoblot assay; anti-HCV, antibodies against HCV; s:co, signal-to-cutoff.
†A confirmed case requires laboratory confirmation. Laboratory criteria consist of at least 1 of the following: a positive result for a HCV RIBA, a positive result for a nucleic acid test for HCV RNA, an HCV genotype, or enzyme immunoassay with detection of anti-HCV and a s:co ratio predictive of a true positive result for a particular assay (see www.cdc.gov/ncphi/disss/nndss/casedef/hepatitisccurrent.htm for the 2005 Council of State and Territorial Epidemiologists/Centers for Disease Control and Prevention case definition).
‡Excludes New York, New York.
§Cases could be reported with more than minimum laboratory criteria; totals add up to >100%.
¶Other sources of reports included private healthcare providers, facilities such as hospitals and outpatient clinics, and institutions such as prisons, blood banks, and drug treatment centers, among others.